Avalon GloboCare Corp (NASDAQ:ALBT) has received a new patent to add to its portfolio.
The Freehold, New Jersey-based company announced the United States Patent and Trademark Office (USPTO) issued a Notice of Publication for U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins."
This patent, a collaborative effort with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT), encompasses the composition and methodology for a groundbreaking technology known as the "QTY Code."
The code has the potential to transform water-insoluble transmembrane receptor proteins into their water-soluble counterparts, thereby expanding the horizon of therapeutic targets for conditions like cancer and diseases.
“Our patented technology can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications,” CEO David Jin explained.
“The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications, including, among others, mitigation of the ‘cytokine storm’ associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.”
Avalon GloboCare is a trailblazing innovator in precision diagnostics and clinical laboratory services.